AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Astrazeneca (AZN) Rises Higher Than Market: Key Facts
Astrazeneca (AZN) concluded the recent trading session at $203.49, signifying a +1.37% move from its prior day's close.
AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial
AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant improvement in how long patients with a common liver cancer lived before their disease worsened, in a late-stage trial.
AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa
AstraZeneca reports phase III data showing efzimfotase alfa improves bone health in children with HPP, with mixed adult results and an overall favorable safety profile.
US bank sees AstraZeneca HPP drug data as supportive of $2.6bn forecast with upside to $4.4bn despite mixed trial results
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has reported mixed phase three trial data for efzimfotase alfa, its treatment for hypophosphatasia, a rare genetic disease that impairs the body's ability to mineralise bones and teeth. Results from the paediatric trials, known as MULBERRY and CHESTNUT, were positive, but the HICKORY trial in adults and adolescents produced a more complicated picture.
AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results
The company said the results support the drug's potential to transform the treatment of hypophosphatasia and it plans to submit data to regulators as soon as possible.
Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patients
Friday's positive trial results for tozorakimab mark a significant inflexion point for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), arriving at a moment when the market had all but written off the drug's prospects and at a time when the pharmaceutical industry has been struggling to find treatments that work across the full spectrum of chronic obstructive pulmonary disease. COPD, a progressive lung condition affecting hundreds of millions of people worldwide, has long resisted a one-size-fits-all treatment approach, and the segment that has proved most stubborn is patients with low levels of eosinophils, a type of white blood cell, who account for roughly 35% of sufferers and for whom existing therapies offer limited benefit.
Guggenheim Raises AstraZeneca Price Target Ahead of Q1 Earnings
AstraZeneca PLC (NASDAQ:AZN) has delivered a solid trailing 12 months, with shares up 31.43% over the past year.
AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies
AstraZeneca jumps as tozorakimab hits primary goals in two phase III COPD trials, cuts exacerbations and shows promise in a disease with limited options.
Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
In the latest trading session, Astrazeneca (AZN) closed at $188.42, marking a +2.74% move from the previous day.
AstraZeneca shares rise to top of FTSE 100 as COPD drug clears two pivotal trials
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares rose 3% to 14,230p, placing the drugmaker at the top of the FTSE 100 leaderboard on a subdued Friday session, after its experimental COPD treatment tozorakimab succeeded in two late-stage clinical trials. The results mark the first positive phase III readout from a programme of more than 20 major data releases AstraZeneca expects to deliver in 2026, each adding weight to the company's ambition to reach $80 billion in annual revenue by 2030.
AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials
Tozorakimab met the primary goal in two late-stage clinical trials, reducing the rate at which patients' symptoms worsened, the company said.
AstraZeneca drug reduces COPD flare ups in late-stage trials
AstraZeneca said on Friday said its experimental treatment tozorakimab met the main goal in two late-stage trials and showed a meaningful reduction in flare ups of chronic obstructive pulmonary disease, also known as "smoker's lung".
